Levofolinic acid

DRUG3 trials

Sponsors

Hoffmann-La Roche, National Cancer Institute, Naples

Conditions

Colorectal CancerGastric CancerRectal Cancer

Phase 2

A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer

CompletedNCT01383707

Hoffmann-La RocheColorectal Cancer

Start: 2011-08-12End: 2016-05-18Updated: 2017-06-14

Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer

CompletedNCT01481545

National Cancer Institute, NaplesRectal Cancer

Start: 2006-12-31End: 2016-12-31Updated: 2021-02-03

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer

CompletedNCT01590719

Hoffmann-La RocheGastric Cancer

Start: 2012-07-31End: 2014-10-31Updated: 2016-08-09

Related Papers

Dissecting gastric cancer biology and how and when to use immunotherapy

Annals of Oncology2018-10-01

Abstract 5571: Changes in plasma genomic abnormalities at chromosome 8 and 20 predict treatment response and monitor disease progression in advanced gastric cancer

Cancer Research2018-07-01

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.

2016-07-0889 citations

False-negative rate for HER2 testing in 738 gastric and gastroesophageal junction cancers (GEC) from two global randomized clinical trials.

Journal of Clinical Oncology2015-01-2015 citations